The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa

Dermatology. 2009;219(2):143-7. doi: 10.1159/000228337. Epub 2009 Jul 8.

Abstract

Background: A previous limited study showed promising results of combined oral treatment with rifampicin 600 mg and clindamycin 600 mg for 10 weeks.

Objective: To expand and to validate the basis for this therapy, we reviewed the response to different treatment durations.

Method: A retrospective study in 34 patients.

Results: Twenty-eight of 34 patients (82%) experienced at least partial improvement, and 16 (47%) showed a total remission. The maximum effect of treatment appeared within 10 weeks. Following total remission, 8 of 13 (61.5%) patients treated as mentioned above experienced a relapse after a mean period of 5.0 months. Nonresponders were predominantly patients with severe disease.

Conclusion: Combination treatment with oral rifampicin and clindamycin is a promising treatment option for hidradenitis suppurativa, despite the frequent occurrence of diarrhea as a side effect. The length and the dosage of treatment are not yet firmly established.

MeSH terms

  • Administration, Oral
  • Adult
  • Clindamycin / administration & dosage*
  • Cohort Studies
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Hidradenitis Suppurativa / diagnosis
  • Hidradenitis Suppurativa / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Patient Satisfaction
  • Quality of Life
  • Retrospective Studies
  • Rifampin / administration & dosage*
  • Severity of Illness Index
  • Treatment Outcome
  • Young Adult

Substances

  • Clindamycin
  • Rifampin